Skip to main content
AURX logo

Nuo Therapeutics, Inc. (AURX) Stock: Price, Forecast & Analyst Target

Nuo Therapeutics, Inc. (AURX) — price $1.09 (0.00%), as of the Nov 18, 2026 trading session; market cap $52.8M.

Educational signal · not a buy or sell recommendation · How to read this

$1.09 $0.00 (0.00%) Market Cap $52.8M

Nuo Therapeutics, Inc. · AURX

Nuo Therapeutics, Inc. is a Houston-based biotechnology firm specializing in regenerative therapies, leveraging proprietary cell-based technologies to harness the body's natural healing processes. The company primarily develops and commercializes autologous platelet-based treatments for the chronic wound care market in the United States.

Price as of Nov 18, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • RLYB · Rallybio Corporation · 82 /100
  • ICCC · ImmuCell Corporation · 82 /100
  • ORMP · Oramed Pharmaceuticals Inc. · 72 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$1.09
Change on the day0.00%
52-week range$0.77 – $2.36
Market capitalisation$52.8M
Shares traded on the day40

Price & events

Other perspectives

Council score for Nuo Therapeutics (AURX): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

4 lenses, 4 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Strong
Gross Margin Strong

Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Nuo Therapeutics (AURX), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Nuo Therapeutics, Inc. (AURX) is the company analyzed here. It employs 10 people and is led by David E. Jorden. In Q3 FY2026 it reported revenue of $2M and net income of -$424,928. The market values it at $52.8M.

2 · Latest results

What do the latest results show for Nuo Therapeutics (AURX)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of $2M. Against analyst estimates the company has EPS beat 0 of the last 4 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026$2M-$424,928-$0.01 (diluted)
Q2 FY2026$2M-$277,601-$0.01 (diluted)
Q1 FY2026$1M-$618,466-$0.01 (diluted)
Q4 FY2025$1M-$578,480-$0.01 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Nuo Therapeutics (AURX)?

Short answer · as of

The distress and quality screens read Altman Z -11.48 · Piotroski F 3. Trailing ratios: ROE 132.7% · ROA -69.6% · current ratio 0.81 · earnings yield -3.6% · free-cash-flow yield -4.0%.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -11.48 sits in the distress zone (elevated bankruptcy risk).
  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
  • Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at Nuo Therapeutics (AURX)?

Short answer · as of

Current published price targets run low $3.00 · high $3.00 · consensus $3.00 · median $3.00 against a quoted price of $1.09 (as of Nov 18, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.
  • Fewer than two score snapshots exist, so no score trend is shown.

Checked against the records this page reads, on the dates shown above.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$3.00 – $3.00
Consensus target
$3.00
Median target
$3.00

Consensus record · Captured .

Measured against a quoted price of $1.09 (as of Nov 18, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 6, 2026

Transactions
26
Identified insiders
5
Purchases
2
Sales
0
Other transactions
24

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held AURX in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported AURX in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Common Questions About AURX

These answers are editorial: 1 of these 8 answers is drawn from the AURX research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is AURX a good stock to buy?

Stock Expert AI does not rate AURX buy, sell or hold. Nuo Therapeutics, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the AURX stock price today?

The last price recorded for Nuo Therapeutics, Inc. (AURX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the AURX price target?

The analyst consensus price target for Nuo Therapeutics, Inc. (AURX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What does Nuo Therapeutics, Inc. do?

Nuo Therapeutics, Inc. is a biotechnology company specializing in regenerative therapies, primarily focused on the chronic wound care market in the United States.

What are the key factors to evaluate for AURX?

Evaluate AURX on fundamentals, analyst consensus, and risk factors. To weigh it, read the analyst view under Analyst targets & estimates on this page. Core Technology: Specializes in autologous blood separation for platelet-based therapies targeting the chronic wound care market. Not financial advice.

How frequently does AURX data refresh on this page?

AURX's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven AURX's recent stock price performance?

Nuo Therapeutics, Inc. (AURX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized proprietary technology for autologous platelet-based therapy. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider AURX overvalued or undervalued right now?

Nuo Therapeutics, Inc. (AURX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 19 figures on this page — 13 from Financial Modeling Prep (FMP) and 6 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.